2m 2m 2m 2m 2m 2m 2m
- $7.1BMarket Cap
- 5.38%1-Year Change
- Medical Instruments & SuppliesIndustry
Repligen (RGEN)
Key Performance
More- Earnings Score: 55
- Momentum Score: 23
- True Yield: N/A
- Financial Health Score: 64
Latest Research & News
The global single-use bioprocessing market is expected to grow from USD 30.12 billion in 2025 to USD 122.92 billion by 2035 at a CAGR of 15.1%. Driven by technological breakthroughs in bioreactor scalability (up to 6,000L), 40-50% CAPEX reductions, and FDA approvals of 16 single-use-manufactured biologics in 2024, the market is becoming the standard for commercial biomanufacturing. Major players are expanding capacity significantly, with CDMOs like WuXi Biologics managing substantial backlogs.
01/20/2026, 12:38 PM • GlobeNewswire
The global continuous bioprocessing market is projected to grow from USD 319.77 million in 2025 to USD 2,331.98 million by 2035 at a CAGR of 21.98%. Driven by demand for biosimilars and complex biologics, manufacturers are shifting from traditional fed-batch to continuous methods, achieving 50% cost reductions and significant sustainability improvements. North America leads with 39% market share, while Asia Pacific rapidly expands capacity. Major pharmaceutical and biotech companies are deploying billions in capital investments to modernize manufacturing infrastructure.
01/16/2026, 12:38 PM • GlobeNewswire
Filtration in Biologics Market: Trends, Growth Drivers and Opportunities (2024–2034)
The filtration in biologics market is projected to experience significant growth from 2024 to 2034, driven by increasing demand for monoclonal antibodies, vaccines, and cell and gene therapies, with North America leading and Asia Pacific showing the fastest growth potential.
10/24/2025, 10:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Key Executives
- Olivier Loeillot
- Jason K. Garland
- James R. Bylund
- Ralf Kuriyel
- Anthony J. Hunt
Current Ownership Distribution
- Institutions1.0B (59.31%)
- Mutual Funds690.0M (40.38%)
- Insiders5.2M (0.31%)
- Other0 (0.00%)